Reports Q2 revenue $26.9M, consensus $25.7M. “We are encouraged by the progress we made in the second quarter in building our hematology/oncology company,” said Raul Rodriguez, Rigel’s president and CEO. “We delivered strong year-over-year revenue growth for TAVALISSE in ITP and hired our dedicated institutional sales team to drive our commercial launch of REZLIDHIA with a focus on awareness and education with healthcare professionals. We also continued to advance our current development programs while evaluating opportunities to expand our hematology/oncology business through internal and external opportunities.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RIGL: